Clinical Trial Search

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in the Pilot Part of the Study — 2; 1 Participants

Primary: Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Day 169 in Short Term Period — 91.5; 83.1 Percentage of participants

Primary: Treatment Emergent Non-Serious Adverse Events With Greater Than 5% Frequency — 6; 9; 4; 3 Participants

Primary: Number of mUFC (Urinary Free Cortisol) Responders by Randomized Dose Group — 12; 21 Responders

Primary: Presence of Carcinoma of the Prostate as Measured by Biopsy — 48; 49 participants — p=0.73

Primary: Mean Change From Baseline in Total Daily OFF Time (Hours) to Week 20 (Including Last Observation Carried Forward [LOCF] Data) — -0.96; -0.93; -0.76 Hours

Primary: Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase — -23.25; -9.80 Percentage change

Primary: Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) — -20.95; -26.34; -34.49 Percent…

Primary: Change From Baseline to Week 24 in SIB Total Score — 2.6; 0.4 Scores on a scale

Primary: Complete Healing of the Study Ulcer by Week 16. — 201; 176 participants — p=0.1030

Primary: Juniper Asthma Control Questionnaire (ACQ) Results — -0.15; -0.38 units on a scale

Primary: Changes in WOMAC (Western Ontario and McMaster University Osteoarthritis Index) Totol Score — 56.0; 53.3; 34.8; 31.5 Score

Primary: Change From Baseline in Total Score on the Young Mania Rating Scale (YMRS) (LOCF Data Set) — -11.54; -13.57 Units on a scale — p=0.058

Primary: Latency To Persistent Sleep (LPS) — 37.5; 24.4; 20.9; 12.8 Minutes

Primary: Areal Bone Density by DXA — 0.88; 0.89 g/cm2